The onset of toxicity following an overdose of intravenously administered methohexital will be within seconds of the infusion. If methohexital is administered rectally or is ingested, the onset of toxicity may be delayed. The manifestations of an ultrashort-acting barbiturate in overdose include central nervous system depression, respiratory depression, hypotension, loss of peripheral vascular resistance, and muscular hyperactivity ranging from twitching to convulsive-like movements. Other findings may include convulsions and allergic reactions. Following massive exposure to any barbiturate, pulmonary edema, circulatory collapse with loss of peripheral vascular tone, and cardiac arrest may occur.
An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Methohexital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methohexital. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Methohexital. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Methohexital. |
| Hydrocodone | Methohexital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methohexital. |
| Magnesium sulfate | The therapeutic efficacy of Methohexital can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Methohexital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Methohexital may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methohexital. |
| Mirtazapine | Methohexital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Methohexital. |
| Orphenadrine | Methohexital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Methohexital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Methohexital. |
| Pramipexole | Methohexital may increase the sedative activities of Pramipexole. |
| Ropinirole | Methohexital may increase the sedative activities of Ropinirole. |
| Rotigotine | Methohexital may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Methohexital. |
| Suvorexant | Methohexital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Methohexital. |
| Thalidomide | Methohexital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Methohexital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Mefloquine | The therapeutic efficacy of Methohexital can be decreased when used in combination with Mefloquine. |
| Orlistat | Orlistat can cause a decrease in the absorption of Methohexital resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Acetaminophen | The metabolism of Acetaminophen can be increased when combined with Methohexital. |
| Propacetamol | The metabolism of Propacetamol can be increased when combined with Methohexital. |
| Chloramphenicol | The metabolism of Methohexital can be decreased when combined with Chloramphenicol. |
| Doxycycline | The serum concentration of Doxycycline can be decreased when it is combined with Methohexital. |
| Felbamate | The serum concentration of Methohexital can be increased when it is combined with Felbamate. |
| Griseofulvin | The serum concentration of Griseofulvin can be decreased when it is combined with Methohexital. |
| Lamotrigine | The serum concentration of Lamotrigine can be decreased when it is combined with Methohexital. |
| Mianserin | The therapeutic efficacy of Methohexital can be decreased when used in combination with Mianserin. |
| Primidone | The risk or severity of adverse effects can be increased when Primidone is combined with Methohexital. |
| Methylphenobarbital | The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methohexital. |
| Phenobarbital | The risk or severity of adverse effects can be increased when Phenobarbital is combined with Methohexital. |
| Pyridoxine | The metabolism of Methohexital can be increased when combined with Pyridoxine. |
| Teniposide | The serum concentration of Teniposide can be decreased when it is combined with Methohexital. |
| Ulipristal | The serum concentration of Ulipristal can be decreased when it is combined with Methohexital. |
| Voriconazole | The serum concentration of Voriconazole can be decreased when it is combined with Methohexital. |
| Topotecan | Methohexital may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Methohexital. |
| Sodium oxybate | Methohexital may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Tetracosactide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Methohexital. |
| Aminophylline | The therapeutic efficacy of Methohexital can be decreased when used in combination with Aminophylline. |
| Meperidine | Methohexital may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine. |
| Somatostatin | The risk or severity of adverse effects can be increased when Somatostatin is combined with Methohexital. |
| Ethanol | Methohexital may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Methohexital may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Methohexital. |
| Citalopram | The risk or severity of adverse effects can be increased when Methohexital is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Methohexital is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Methohexital is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Methohexital is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Methohexital is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Methohexital is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Methohexital is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Methohexital is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Methohexital is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Methohexital is combined with Dapoxetine. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Methohexital is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Methohexital is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Methohexital is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Methohexital is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Methohexital is combined with Alaproclate. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Methohexital is combined with Fluvoxamine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Methohexital is combined with Milnacipran. |
| Cyclosporine | The metabolism of Cyclosporine can be increased when combined with Methohexital. |
| Methyclothiazide | The risk or severity of hypotension and orthostatic hypotension can be increased when Methohexital is combined with Methyclothiazide. |
| Chlorthalidone | The risk or severity of hypotension and orthostatic hypotension can be increased when Methohexital is combined with Chlorthalidone. |
| Bendroflumethiazide | The risk or severity of hypotension and orthostatic hypotension can be increased when Methohexital is combined with Bendroflumethiazide. |
| Metolazone | The risk or severity of hypotension and orthostatic hypotension can be increased when Methohexital is combined with Metolazone. |
| Benzthiazide | The risk or severity of hypotension and orthostatic hypotension can be increased when Methohexital is combined with Benzthiazide. |
| Hydroflumethiazide | The risk or severity of hypotension and orthostatic hypotension can be increased when Methohexital is combined with Hydroflumethiazide. |
| Indapamide | The risk or severity of hypotension and orthostatic hypotension can be increased when Methohexital is combined with Indapamide. |
| Chlorothiazide | The risk or severity of hypotension and orthostatic hypotension can be increased when Methohexital is combined with Chlorothiazide. |
| Hydrochlorothiazide | The risk or severity of hypotension and orthostatic hypotension can be increased when Methohexital is combined with Hydrochlorothiazide. |
| Trichlormethiazide | The risk or severity of hypotension and orthostatic hypotension can be increased when Methohexital is combined with Trichlormethiazide. |
| Polythiazide | The risk or severity of hypotension and orthostatic hypotension can be increased when Methohexital is combined with Polythiazide. |
| Quinethazone | The risk or severity of hypotension and orthostatic hypotension can be increased when Methohexital is combined with Quinethazone. |
| Cyclopenthiazide | The risk or severity of hypotension and orthostatic hypotension can be increased when Methohexital is combined with Cyclopenthiazide. |
| Epitizide | The risk or severity of hypotension and orthostatic hypotension can be increased when Methohexital is combined with Epitizide. |
| Protriptyline | The metabolism of Protriptyline can be increased when combined with Methohexital. |
| Amoxapine | The metabolism of Amoxapine can be increased when combined with Methohexital. |
| Desipramine | The metabolism of Desipramine can be increased when combined with Methohexital. |
| Amineptine | The metabolism of Amineptine can be increased when combined with Methohexital. |
| Dimetacrine | The metabolism of Dimetacrine can be increased when combined with Methohexital. |
| Butriptyline | The metabolism of Butriptyline can be increased when combined with Methohexital. |
| Dosulepin | The metabolism of Dosulepin can be increased when combined with Methohexital. |
| Oxaprotiline | The metabolism of Oxaprotiline can be increased when combined with Methohexital. |
| Opipramol | The metabolism of Opipramol can be increased when combined with Methohexital. |
| Amitriptylinoxide | The metabolism of Amitriptylinoxide can be increased when combined with Methohexital. |
| Dibenzepin | The metabolism of Dibenzepin can be increased when combined with Methohexital. |
| Quinupramine | The metabolism of Quinupramine can be increased when combined with Methohexital. |
| Melitracen | The metabolism of Melitracen can be increased when combined with Methohexital. |
| Lofepramine | The metabolism of Lofepramine can be increased when combined with Methohexital. |
| Iprindole | The metabolism of Iprindole can be increased when combined with Methohexital. |
| Imipramine oxide | The metabolism of Imipramine oxide can be increased when combined with Methohexital. |
| Dicoumarol | The metabolism of Dicoumarol can be increased when combined with Methohexital. |
| Phenindione | The metabolism of Phenindione can be increased when combined with Methohexital. |